BioSpace News Archive

Kelyniam Global (KLYG), a maker of custom cranial implants, announced today that it has signed a multi-year distribution agreement with a leading medical device distributor in the neuroscience market.

Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today that it has completed its Series A financing totaling $3 million, before expenses, to fund operations and advance Hoth’s BioLexa Platform.

MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors.

Company Provides Update on Late-stage Microbiome-focused Product Candidates.

Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, announced today the successful completion of the first robotic-assisted peripheral vascular intervention procedure using the recently FDA-cleared CorPath GRX System.

Syndax Pharmaceuticals, Inc. today announced eight presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting

Kite to Receive Exclusive License to Leverage Sangamo’s Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology [22-February-2018] SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 /PRNewswire/ -- Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have e

Fourth Quarter 2017 Revenues of $595.1 million, up 15.8% Versus Prior Year Period; up 12.6% on Constant Currency Basis

Former Lilly Executive will oversee Development, Regulatory Affairs and Quality

Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360 today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360’s supplemental New Drug Application (sNDA)